# Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension

> **NCT00366119** · PHASE4 · UNKNOWN · sponsor: **Pacific Pharmaceuticals** · enrollment: 86 (—)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Ramipril

## Key facts

- **NCT ID:** NCT00366119
- **Lead sponsor:** Pacific Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 86 (—)
- **Last updated:** 2007-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366119, "Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00366119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*